SGLT2-话题@MedSci

#SGLT2#

82篇内容 | 2980人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1503819, encodeId=40fa150381925, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=JAMA子刊：SGLT2抑制剂与2型糖尿病和痛风发病率的关系, objectType=article, longId=220869, objectId=83b52208691b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83b52208691b, replyNumber=0, likeNumber=69, createdTime=2021-11-24, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83b52208691b, moduleTitle=JAMA子刊：SGLT2抑制剂与2型糖尿病和痛风发病率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83b52208691b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503818, encodeId=51b91503818b8, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果, objectType=article, longId=219505, objectId=2f0321950544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0321950544, replyNumber=0, likeNumber=74, createdTime=2021-10-31, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0321950544, moduleTitle=Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0321950544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503817, encodeId=2cdd150381e06, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Lancet子刊：新型降糖药SGLT2抑制剂达格列净能明显保护糖尿病肾病！, objectType=article, longId=218938, objectId=389521893854, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=389521893854, replyNumber=0, likeNumber=81, createdTime=2021-10-22, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=389521893854, moduleTitle=Lancet子刊：新型降糖药SGLT2抑制剂达格列净能明显保护糖尿病肾病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=389521893854)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503816, encodeId=c5531503816e0, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响, objectType=article, longId=218049, objectId=35582180496e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35582180496e, replyNumber=0, likeNumber=75, createdTime=2021-10-04, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35582180496e, moduleTitle=Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35582180496e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503815, encodeId=8eb8150381516, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, objectType=article, longId=215519, objectId=1da5215519ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da5215519ba, replyNumber=0, likeNumber=82, createdTime=2021-08-11, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da5215519ba, moduleTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da5215519ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503814, encodeId=6fb7150381404, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系, objectType=article, longId=214922, objectId=a0cf214922cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0cf214922cb, replyNumber=0, likeNumber=59, createdTime=2021-07-29, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0cf214922cb, moduleTitle=Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0cf214922cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503813, encodeId=53cc150381342, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响, objectType=article, longId=210247, objectId=eae121024e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae121024e21, replyNumber=0, likeNumber=91, createdTime=2021-04-22, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae121024e21, moduleTitle=Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae121024e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503812, encodeId=e76515038120d, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！, objectType=article, longId=208138, objectId=ca0a2081382a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0a2081382a, replyNumber=0, likeNumber=62, createdTime=2021-03-09, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0a2081382a, moduleTitle=新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0a2081382a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503811, encodeId=3634150381152, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较, objectType=article, longId=204761, objectId=2bc7204e618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bc7204e618a, replyNumber=0, likeNumber=0, createdTime=2020-12-23, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bc7204e618a, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bc7204e618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503810, encodeId=05ee15038102b, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与全因死亡率, objectType=article, longId=204445, objectId=1c7d204445bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c7d204445bf, replyNumber=0, likeNumber=68, createdTime=2020-12-14, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c7d204445bf, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与全因死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c7d204445bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503809, encodeId=f68a150380986, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Circulation：SGLT2抑制剂恩格列净也具有利尿作用, objectType=article, longId=202871, objectId=fd232028e1c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd232028e1c1, replyNumber=0, likeNumber=76, createdTime=2020-11-05, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd232028e1c1, moduleTitle=Circulation：SGLT2抑制剂恩格列净也具有利尿作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd232028e1c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503808, encodeId=30961503808d7, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？, objectType=article, longId=202549, objectId=a65c202549a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65c202549a6, replyNumber=0, likeNumber=52, createdTime=2020-10-29, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65c202549a6, moduleTitle=JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a65c202549a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503807, encodeId=53f5150380e78, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险, objectType=article, longId=201239, objectId=bc36201239f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc36201239f3, replyNumber=0, likeNumber=90, createdTime=2020-09-27, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc36201239f3, moduleTitle=BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc36201239f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503806, encodeId=5635150380665, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响, objectType=article, longId=200115, objectId=f8af20011537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8af20011537, replyNumber=0, likeNumber=0, createdTime=2020-09-03, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8af20011537, moduleTitle=Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8af20011537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503805, encodeId=687c1503805a2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, objectType=article, longId=197735, objectId=bb3a19e7357e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3a19e7357e, replyNumber=0, likeNumber=78, createdTime=2020-07-20, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3a19e7357e, moduleTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3a19e7357e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503804, encodeId=3a9515038043f, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=66, createdTime=2020-06-17, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503803, encodeId=10f015038039b, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰, objectType=article, longId=194242, objectId=464e1942427f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=464e1942427f, replyNumber=0, likeNumber=80, createdTime=2020-05-17, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=464e1942427f, moduleTitle=FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=464e1942427f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503802, encodeId=c73a150380294, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险, objectType=article, longId=193883, objectId=9ea41938837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ea41938837b, replyNumber=0, likeNumber=43, createdTime=2020-05-11, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ea41938837b, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ea41938837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=66, createdTime=2020-05-08, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503800, encodeId=71e51503800bc, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险, objectType=article, longId=193278, objectId=e2d81932e81e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2d81932e81e, replyNumber=0, likeNumber=78, createdTime=2020-05-02, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2d81932e81e, moduleTitle=BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2d81932e81e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT2

2020-05-29

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

JAMA子刊：SGLT2抑制剂与2型糖尿病和痛风发病率的关系

2021-11-24

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Nat Med：SGLT2抑制剂达格列净治疗射血分数正常心衰的效果

2021-10-31

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Lancet子刊：新型降糖药SGLT2抑制剂达格列净能明显保护糖尿病肾病！

2021-10-22

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响

2021-10-04

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病

2021-08-11

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系

2021-07-29

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响

2021-04-22

仁心济世 (审核中...)

前往app查看评论内容

#SGLT2#

新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！

2021-03-09

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较

2020-12-23

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Diabetes Obes Metab：SGLT2抑制剂与全因死亡率

2020-12-14

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Circulation：SGLT2抑制剂恩格列净也具有利尿作用

2020-11-05

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？

2020-10-29

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

BMJ：SGLT2抑制剂可降低II型糖尿病患者的心血管事件风险

2020-09-27

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响

2020-09-03

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险

2020-07-20

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-06-17

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰

2020-05-17

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险

2020-05-11

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2020-05-08

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险

2020-05-02

科室
- - 订阅+
  - 更多科室
工具
服务